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Hormonal measurements in some women with hir-
sutism often reveal little or no elevation in androgen 
levels to explain the disorder. Thus, it has been postu-
lated that increased sensitivity of the hair follicle to 
androgen may contribute to the development of hirsut-
ism in such patients. We, therefore, sought androgen 
receptor abnormalities in skin fibroblasts cultured from 
10 hirsute women (ages 17-43) and normal or mildly 
elevated plasma testosterone levels (28-82 ng/dl). An-
drogen receptor content (Ro) and binding affinity (Kd) 
in cultured pubic skin fibroblasts were measured using 
a dispersed, whole cell assay. Ten such cell lines from 
these women were compared with 19 pubic skin cell 
lines from 9 normal volunteers (6 males and 3 females) 
and from 10 other subjects (males with gynecomastia or 
hypospadias). There was no statistically significant dif-
ference in the mean androgen receptor content (11,600 
± 2700 (SE) sites/cell fibroblasts vs 7900 ± 700 sites/ 
cell or binding affinity (2.0 ± 0.3 (SE) x 10-9 M vs 1.5 ± 
0.2 x 10-9 M, respectively) between the patients' fibro-
blasts and those of the controls. 
We conclude that hirsutism cannot be explained by 
abnormalities in fibroblast androgen receptor number 
or affinity. These observations do not exclude the pos-
sibility that other mechanisms might lead to increased 
peripheral androgen sensitivity in such patients. 
Hirsutism in women who have norma l o r mildly elevated 
plasma testosterone leve ls , and who h ave no known etiology to 
accoun t for elevated androgen production, is often termed 
idiopathic hirsut ism (IH) . Such patients may or may not have 
associated menstrual abnormaliti es. Several lines of evidence 
suggest t hat IH is an androgen-dependent disorder. First, the 
usua l onset of the disorder is at puberty, when risin g androgen 
leve ls sti mulate pubic and axillary hair development. Second, 
the distribution of hair pa rallels that of androgen-dependent 
hair in males, which includes areas such as the upper lip, chin, 
sideburns, and chest [1] . Third , women with IH, as a group, 
have e levated levels of free plasma testosterone a nd elevated 
testosterone blood production rates compa red to normal women 
[2,3]. Fourth, therapeutic agents that suppress adrenal or ovar-
ian and roge n production, or that block the action of testoster-
Manusc ript received April 2, 1984; accepted for publication July 10, 
1984. 
• Portions of this work were presented in abstract form at the 62nd 
Annual Meeting of the Endocrine Society, Washington, D.C., June 
1980. 
t Present address: Box 396, National Nava l Medical Center, Be-
thesda, Maryland 20814. 
Reprin t requests to: Charles Eil, M.D. , Box 396, National Naval 
Medical Center, Bethesda, Maryland 20814. 
Abbreviations: 
DHT: 11 ,2 ,4 ,5,6,7 -"H (N) ]dihydrotestosterone 
IH : idiopathic hirsutism 
IMEM: improved Eagle's minimal essential medium 
Ku: binding affini ty 
PBS: phosphate-buffered saline 
~,: receptor content 
62 
one on the hair follicle, reduce the rate of hair growth in many 
hirsute women [4-12]. 
Despite this evidence, several observations have cast doubt 
on whether IH can be explained entirely on the basis of elevated 
androgen production. Some women with IH have hirsutism 
despite normal circulating levels of free and total testosterone. 
Other women have high androgen levels, similar to the levels 
usually seen in IH, but do not have hirsutism [5). These findings 
have suggested that heightened end-organ sensitivity to andro-
gen might play an important role in the pathogenesis of hir-
sutism [13] . Three mechanisms that might cause such an 
increase in sensitivity are an increase in the activity of periph-
eral 5a-reductase, which converts testosterone to the more 
active dihydrotestosterone, an increase in androgen receptor 
number (Ro) or binding affinity (Kd), or an increase in the 
efficiency of processes subsequent to receptor binding. Since 
5a-reductase activity in the pubic hair follicles of hirsute 
women has been shown to be similar to that of normal women 
[14], we sought to test the hypothesis that hirsutism may result 
from enhanced androgen receptor activity by measuring andro-
gen Ro and Kd in pubic skin fibroblasts grown from 10 hirsute 
women and from 19 control subjects. 
MATERIALS AND METHODS 
S ubjects 
All patients included in t his study showed moderate to severe hir-
sutism according to the criteria of Lorenzo [1] and presented for 
evaluatio n and t reatment of this condition. Eight of the 10 patients 
had terminal hair in the midsternal region which occurs in less than 
3% of normal women [15]. The patients had no evidence of the 
following disorders: adrenal or ovarian tumors, Cushing's syndrome, or 
congenital adrenal hyperplasia (either the classic or attenuated form s). 
None showed evidence of vir il ization such as clitoromegaly, deepening 
of the voice, or a male muscular habi tus. Many were obese and only 4 
had normal menses. The remaining 6 patients had oligomenorrhea c r 
amenorrhea. Two patients had enlarged or polycystic ovaries. Further 
clinical and laboratory features of these patients are provided in Table 
I. 
Normal control subjects consisted of men and women volunteers 
between the ages of 18-24 who consented to skin biopsy and several 
men with gynecomastia or hypospadias who also consented to biopsy. 
Since the pubic skin fibroblast androgen receptor characte ristics from 
these latte r subjects have been shown to be normal in earlier studies 
[1 7], these data were pooled with those for the normal volunteers. 
Additionally, since our data and that of several published studies 
showed no difference in fibroblast androgen receptor number or affi ni ty 
between normal men and women [18- 21], we pooled male and female 
control data. 
Materials 
Collagenase (Type 1 from Cl. histolyticum) and Tricene (N-
Tris[hydroxymethyl]methyl glycine) were purchased from Sigma 
Chemical Co. (St. Louis, Missouri) . Fetal calf serum (mycoplasma and 
virus screened) was obtained from Grand Island Biological Co. (Grand 
Island, New York). Tris (Tris[hydroxymethyl]aminomethane) was ob-
tained from Bethesda Research Laborator ies, Inc. (Rockville, Mary-
land) . [1,2,4,5,6,7-3H(N)]dihydrotestosterone (DHT), 123- 133 Cif 
mmol, and liquid scintillation fluid (Aquasol) were from New England 
Nuclear (Boston, Massachusetts). Insul in (lletin, U-100) was from Eli 
Lilly and Company (Indianapolis, Indiana). Tissue culture flask s (75 
em" and 150 cm2) were purchased from Costar (Cambridge, Massachu-
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TABLE f. Clinical and laboratory features of women with hirsutism 
Patient Age Percent Duration of Total LH FSH Prolact.in DHAS' 24- h Urine des irab le Mensesb hirsutism testoste rone 17 -ketosteroids Comments no. (years) weight" (yea rs) (ng/dl) (m iU/ml) (mlU/ ml) (ng/ ml) (l'g/dl) (mg) 
1 36 149 N 24 36 17 13 15 121 10 
2 29 147 N 10 50 10 6 12 303 16 Acne 
3 26 145 N 13 28 10 13 8 349 14 Polycystic ovariesd 
4 26 230 A 12 38 14 11 11 234 13 Acne 
5 24 106 0 7 78 20 11 23 280 14 
6 33 193 0 20 82 17 10 7 132 10 
7 17 203 0 3 73 20 17 21 186 10 Generali zed sca lp 
hair loss 
8 31 149 0 16 75 22 8 6 237 ND' 
9 43 141 N 16 46 36 14 9 15 5 
10 34 100 0 18 52 57 14 7 36 6 Bilate rally en larged 
ovaries1 
Mean± SEM 30 ± 3 156 ± 12 14 ± 3 56± 6 22 ± 4 12 ± 1 12 ± 2 189 ± 34 11 ± 1 
Normal range 20-60 5-25 5- 25 <30 60-380 6- 15 
" Derived from the medium-frame ideal body weight. estimates of the Society of Actuaries [1 6]. 
b N = normal; 0 =oligomenorrhea; A = amenorrhea (no menses within 12 months). 
" DHAS, dehydroepiandrosterone sulfate. 
'
1 Enlarged cystic ovaries by physical examination and ultrasound. 
• ND, not determined. 
I Enlarged ovaries by physical examination. 
setts), Falcon (Oxnard, Californ ia), and Corning Glass Works (Corning, 
New York). Petri dishes (60 mm) were a lso from Falcon. Nonradioac-
tive methyltrienolone (R1881) was a gift from Dr. J. P. Raynaud, 
Roussel UC LAF (Romainville, France). All tissue culture media, tryp-
sin -EDTA solutions, and phosphate-buffered sa line (PBS) were pre-
pared and supplied by the National Institutes of Health Media Unit. 
Cell Culture 
Fibroblast st rains were established from pubic skin specimens ob-
tained by punch biopsy. The specimens were finely minced in 60- mm 
Petri dishes containing 4- 5 ml of Medium A consisting of improved 
Eagle's minimal essentia l medium (IMEM) supplemented with 10% 
fetal calf se rum , 10- 7 M insu lin, collagenase (2 mg/ ml), penicillin (100 
U/m l) , streptomyc in (100 1-'g/ ml), and glu tamine (0.584 g/liter). This 
medium was freshly prepared for eac h sample and filtered through a 
Swinnex-13 Millipore filter (Bedford, Massachusetts) immediately 
prior to use. After 48 h at 37"C in t he presence of 5% CO, in a 
humidified incubator, t he medium was changed to a growth medium 
(Medium B) consisting of Medium A without collagenase. When grown 
to confluence (usua lly within 3-4 weeks), t he cells were disrupted with 
0.05% trypsin -0.02% EDTA in saline at 37•c and passed serially into 
larger flasks (75 cm2 and 150 cm2). 
Whole Cell ( 'H) DHT Binding Assay 
Fibroblasts were grown to con fluence in 5 or 6 150-cm2 t issue cu lture 
flasks for routine assay. This usually required 5-6 weeks from the time 
of t he ini tia l seeding of the cell line. Two days prior to assay the 
medium was changed to Medium C (Medium B without fetal ca lf 
serum). This was repeated again 24 h prior to assay. The remainder of 
the procedure has been previously described [18]. The results were 
calcula ted by Scatcha rd analyses and binding capacity was expressed 
as binding sites/ce ll [22 ]. 
Hormone Assays 
Serum testosterone LH, FSH, prolactin, and dehydroepiandroster-
one sulfate were measured by radioimmunoassay as previously de-
scribed [23-27]. Urine 17-ketosteroids were measured by Bioscience 
Laboratories (Columbia, Maryland). 
Statistica l Analysis 
Statistical analys is of the data was performed using Student's t-test 
and the Wilcoxon rank sum test .. 
RESULTS 
Clinical Data 
The pertinent clinical cha racte ristics and laboratory data of 
the patients are s hown in Table I. The ages of t he patients 
ranged from 17-43 with a mean of 30 years. Hirsutism was 
present an average of 14 years. Many had irregular menses and 
TABLE II. Androgen receptor characteristics of cultured skin 
fibroblasts 
Cell line 
Hirsute women 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mean ± SEM 
Controls (n = 19) 
Mean± SEM 
R. (sites/ce ll ) 
6,610 
4,510 
8,590 
10,160 
4,500 
15,450 
29,110 
25,220 
6,860 
5,390 
11,600 ± 2,700" 
7,900 ± 700 
• Not signi fi cantly different from normal controls. 
Kd (x 10·• M) 
1.71 
0.57 
3.00 
2.36 
1.97 
0.96 
2.50 
3.83 
1.10 
2.25 
2.0 ± 0.3" 
1.5 ± 0.2 
most were above ideal body weight. Serum testosterone was 56 
± 6 ng/ dl (mean ± SE). Four of the patients had serum 
testosterone levels s ligh t ly above t he normal range (<60 ng/ 
dl). 
Androgen Receptor Data 
The mean [:JH]DHT binding capacity (Ro, s ites/cell ) and 
mean dissociation constants (Kc~) in t he fibroblasts from pubic 
skin of t he women with hirsutism and the controls is s hown in 
Table II. There were no statistica lly sign ificant differences for 
either binding parameter in the patients' cell s when compared 
to t hose for the cells from the control subjects. The individual 
Ro values for all of t he fibroblast stra in s assayed are shown in 
Fig 1. The data from both groups of subjects overlapped, 
although t he binding capacities for 2 of the patient ce ll lines 
(Nos. 7 and 8) were hi gher than for any of t he control cells. 
These patients did not differ in any apparent way from the 
other hirsute women. 
DISCUSSION 
Normal androgen action is a multistep process that depends 
on both n orma l androgen biosynthesis and normal end-organ 
se nsitivity to androgen. In patients with male pseudoherma-
phroditism in whom blood levels of androgens are normal or 
e levated, in vitro studies with fibroblasts cul tured from human 
s kin have been particularly useful in e lucidati ng the mecha-
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FIG 1. Scattergram of binding capacities fo r whole cell binding of 
[' H]DHT in dispe rsed fibroblasts cul tured from pubic skin in normal 
men (•), normal women (e), men with gynecomastia or hypospadias 
(0) , or women with hirsut ism (0). 
nisms of the impairment in androgen action [19,28- 30). Al-
t hough many women with hirsut ism have been shown to have 
increased androgen production [3,31-33], it has been postulated 
that increased end-organ androgen sensit ivity at the hair folli-
cle may also contribute to hirsut ism in these women. Moreover, 
such increased sensit ivity might be the sole pathogenic mech-
anism in women who have no detectable abnormality of andro-
gen production. 
To test this hypothesis we measured androgen binding in 
pubic skin fibroblasts from hirsute and cont rol subjects. Our 
resu lts did not indicate any increase in the number or affinity 
of fibrob last androgen receptors in hirsute women. Further-
more, while these studies were in progress Mowszowicz et a] 
[21), using a monolayer technique, also showed normal andro-
gen receptors in pubic skin fibroblasts from hirsute women. 
Additionally, Sultan et al have shown that pat ients with ado-
lescent hirsutism have normal fibroblast androgen receptors 
[34). Thus, all of the avai lable data suggest that hirsute women 
do not have heightened androgen sensitivity on the basis of 
a ltered androgen receptor number or affinity. These observa-
tions do not exclude the possibi li ty, however, of increased hair 
follicle sensitivity to androgen based upon other mechanisms, 
such as increased local production of androgens from plasma 
precursors [21,35] or increased efficiency of t he steps distal to 
androgen binding to receptor. Additional in vitro studies with 
skin or cultured cells from hirsute women on the factor(s) 
responsible for the striking elevation of plasma 3a,17 {3-andro-
stanediol glucuronide, a marker of increased peripheral andro-
gen action in t hese women [32), may shed some light in this 
regard. 
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